Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Invested Capital: 2019-2025

Historic Invested Capital for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $703.6 million.

  • Keros Therapeutics' Invested Capital rose 32.04% to $703.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $703.6 million, marking a year-over-year increase of 32.04%. This contributed to the annual value of $571.6 million for FY2024, which is 72.04% up from last year.
  • Latest data reveals that Keros Therapeutics reported Invested Capital of $703.6 million as of Q3 2025, which was down 0.45% from $706.7 million recorded in Q2 2025.
  • Keros Therapeutics' Invested Capital's 5-year high stood at $728.9 million during Q1 2025, with a 5-year trough of $211.2 million in Q2 2022.
  • Its 3-year average for Invested Capital is $493.4 million, with a median of $453.9 million in 2024.
  • In the last 5 years, Keros Therapeutics' Invested Capital soared by 1,098.80% in 2021 and then declined by 10.37% in 2022.
  • Over the past 5 years, Keros Therapeutics' Invested Capital (Quarterly) stood at $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then skyrocketed by 72.04% to $571.6 million in 2024, then spiked by 32.04% to $703.6 million in 2025.
  • Its Invested Capital stands at $703.6 million for Q3 2025, versus $706.7 million for Q2 2025 and $728.9 million for Q1 2025.